Haleon plc (NYSE:HLN) Shares Acquired by HighTower Advisors LLC

HighTower Advisors LLC lifted its holdings in shares of Haleon plc (NYSE:HLN) by 27.2% in the 3rd quarter, HoldingsChannel.com reports. The institutional investor owned 350,795 shares of the company’s stock after acquiring an additional 74,970 shares during the period. HighTower Advisors LLC’s holdings in Haleon were worth $3,701,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors have also made changes to their positions in the business. CWM LLC increased its holdings in shares of Haleon by 12.0% in the second quarter. CWM LLC now owns 21,982 shares of the company’s stock valued at $182,000 after buying an additional 2,360 shares in the last quarter. Dynamic Advisor Solutions LLC bought a new position in shares of Haleon in the second quarter valued at $86,000. Sequoia Financial Advisors LLC grew its position in Haleon by 7.4% during the 2nd quarter. Sequoia Financial Advisors LLC now owns 81,943 shares of the company’s stock worth $674,000 after purchasing an additional 5,623 shares in the last quarter. Portside Wealth Group LLC grew its position in Haleon by 2.7% during the 2nd quarter. Portside Wealth Group LLC now owns 44,985 shares of the company’s stock worth $372,000 after purchasing an additional 1,182 shares in the last quarter. Finally, Blue Trust Inc. grew its position in Haleon by 30.0% during the 2nd quarter. Blue Trust Inc. now owns 24,734 shares of the company’s stock worth $210,000 after purchasing an additional 5,712 shares in the last quarter. 6.67% of the stock is currently owned by institutional investors and hedge funds.

Haleon Stock Performance

NYSE:HLN opened at $9.77 on Thursday. Haleon plc has a 12-month low of $7.89 and a 12-month high of $10.80. The company has a quick ratio of 0.58, a current ratio of 0.84 and a debt-to-equity ratio of 0.44. The firm has a market capitalization of $44.20 billion, a PE ratio of 28.72, a price-to-earnings-growth ratio of 2.92 and a beta of 0.28. The firm has a 50-day moving average price of $9.77 and a 200 day moving average price of $9.50.

Analyst Upgrades and Downgrades

Several research firms have weighed in on HLN. Morgan Stanley lifted their price objective on shares of Haleon from $9.90 to $10.95 and gave the stock an “overweight” rating in a research report on Friday, September 20th. UBS Group upgraded shares of Haleon to a “strong-buy” rating in a report on Tuesday, October 1st. One research analyst has rated the stock with a hold rating, four have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Buy” and a consensus price target of $10.95.

Haleon Company Profile

Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands.